Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer

Breast Cancer: Basic and Clinical Research

Volumn 10, Issue , 2016, Pages 77-84

  Twelves, Chris ^a   Awada, Ahmad ^b   Cortes, Javier ^c,d   Yelle, Louise ^e   Velikova, Galina ^a   Olivo, Martin S ^f   Song, James ^f   Dutcus, Corina E ^f   Kaufman, Peter A ^g  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b JULES BORDET INSTITUTE   (Belgium)

^c VALL D'HEBRON INSTITUTE OF ONCOLOGY   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f EISAI INC   (United States)

^g DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Advanced metastatic breast cancer; Capecitabine; Eribulin; Human epidermal growth factor receptor 2; Subgroup analyses; Survival

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERIBULIN; ESTROGEN RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASIA; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; EASTERN EUROPE; FEMALE; GEOGRAPHIC DISTRIBUTION; GOOD CLINICAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; NORTH AMERICA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SOUTH AFRICA; SOUTH AND CENTRAL AMERICA; WESTERN EUROPE;

EID: 84992088913     PISSN: None     EISSN: 11782234     Source Type: Journal    
DOI: 10.4137/BCBCR.S39615     Document Type: Article

References (15)

1. Partridge AH, Rumble RB, Carey LA, et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014;32(29):3307–3329.
2. Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol. 2014;25(10):1871–1888.
3. SEER Fact Sheet. Available at: http://seer.cancer.gov/statfacts/html/breast.html. Accessed August 12, 2015.
4. Kuznetsov G, Towle MJ, Cheng H, et al. Induction of morphological and bio­chemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 2004;64(16):5760–5766.
5. Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001; 61(3):1013–1021.
6. Funahashi Y, Okamoto K, Adachi Y, et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci. 2014;105(10):1334–1342.
7. Yoshida T, Ozawa Y, Kimura T, et al. Eribulin mesilate suppresses experimen­tal metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer. 2014;110(6):1497–1505.
8. Halaven (eribulin mesylate) injection [prescribing information]. Woodcliff Lake, NJ: Eisai Inc.; 2014.
9. Halaven 0.44 mg/ml Solution for Injection [summary of product characteristics]. Hertfordshire: Eisai Europe Limited: 2016.
10. Cortes J, O’Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treat­ment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914–923.
11. Kaufman PA, Awada A, Twelves C, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or met­astatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33(6):594–601.
12. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Breast Cancer; 2015. Available at: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed February 20, 2015.
13. Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014; 106(5):ii:dju055.
14. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–1948.
15. Mancini P, Angeloni A, Risi E, Orsi E, Mezi S. Standard of care and promis­ing new agents for triple negative metastatic breast cancer. Cancers (Basel). 2014; 6(4):2187–2223.